Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Eoganachton Oct 07, 2024 4:52pm
307 Views
Post# 36256802

Durability of Complete Response

Durability of Complete ResponseI'm not exactly sure what is meant by "evaluable" patients. I suppose it refers to the patients who are still in the trial as the NR patients are dropped. The longer pateints keep their CR the more it looks like a complete cure.

4 patients are evaluable at 1080 days. All 4 are CR
CR rate of patients evaluable at 1080 days 100%

5 patients are evaluable at 900 days. All 5 are CR
CR rate of patients evaluable at 900 days 100%

6 patients are evaluable at 720 days. 5 of the 6 are CR
CR rate of patients evaluable at 720 days 83%

8 patients are evaluable at 630 days. 6 of the 8 are CR
CR rate of patients evaluable at 630 days 75%

10 patients are evaluable at 540 days. 9 of the 10 are CR
CR rate of patients evaluable at 540 days 90%

23 patients are evaluable at 450 days. 18 of the 23 are CR
CR rate of patients evaluable at 450 days 78%





<< Previous
Bullboard Posts
Next >>